Compare FedEx Corporation (FDX) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Globus Medical Inc. Class A Common Stock — how do they compare? FedEx Corporation trades at $291.77 (market cap $68.77B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: FedEx Corporation is far larger — about 6.7× Globus Medical Inc. Class A Common Stock's market cap, and FedEx Corporation pays a 1.68% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| FDX | GMED | |
|---|---|---|
Market Cap | $68.77B | $10.25B |
Volume | 914,308 | 1,108,124 |
Sector | Industrials | Health |
52-Week High | $339.35 | $96.82 |
52-Week Low | $189.87 | $58.33 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $98.41B | $9.76B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.28, down 0.33% on the day, with a bearish technical signal. The stock shows solid fundamentals with a P/E of 15.67 and net income margin of 4.68%, though revenue has been flat recently. Recent news includes a $300 million electric truck order and shareholder approval of executive pay. Cash flow is projected to improve significantly in 2026.
The outlook is mixed: strong analyst buy consensus (57%) and a $307.55 price target suggest upside, but technical indicators and rising fuel costs pose near-term risks. Long-term growth depends on execution of cost cuts and capitalizing on industry tailwinds.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
